Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCongress Asset Management Co /ma
Latest Disclosed Ownership612 shares
Latest Disclosed Value $ 273,282
Congress Asset Management Co /ma reports 34.69% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On April 14, 2026 - Congress Asset Management Co /ma filed a 13F-HR form disclosing ownership of 612 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $273,282 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 9, 2026 disclosing 937 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -34.69% during the quarter. The current value of the position is $273,460 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-04-14 2026-03-31 13F Vertex Pharmaceuticals COM 92532F100 612 -325 -34.69 273 -35.61 0.0020
2026-01-09 2025-12-31 13F Vertex Pharmaceuticals COM 92532F100 937 -159,938 -99.42 425 -99.33 0.0030
2025-10-10 2025-09-30 13F Vertex Pharmaceuticals COM 92532F100 160,875 -27,129 -14.43 63,005 -24.72 0.4193
2025-07-16 2025-06-30 13F Vertex Pharmaceuticals COM 92532F100 188,004 428 0.23 83,699 -7.96 0.5741
2025-04-11 2025-03-31 13F Vertex Pharmaceuticals Inc Com COM 92532F100 187,576 40,427 27.47 90,941 53.47 0.6802
2025-01-30 2024-12-31 13F Vertex Pharmaceuticals Inc Com COM 92532F100 147,149 -41,431 -21.97 59,257 -32.44 0.4005
2024-10-28 2024-09-30 13F Vertex Pharmaceuticals Inc Com COM 92532F100 188,580 6,919 3.81 87,705 3.00 0.5980
2024-08-02 2024-06-30 13F Vertex Pharmaceuticals Inc Com COM 92532F100 181,661 180,286 13,111.71 85,148 14,734.15 0.6102
2024-04-11 2024-03-31 13F Vertex Pharmaceuticals Inc Com COM 92532F100 1,375 0 0.00 575 2.68 0.0041
2024-03-04 2023-12-31 13F Vertex Pharmaceuticals Inc Com COM 92532F100 1,375 -19 -1.36 559 15.50 0.0044
2023-11-01 2023-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,394 -125 -8.23 485 -9.36 0.0043
2023-07-27 2023-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,519 0 0.00 535 11.72 0.0046
2023-04-21 2023-03-31 13F Vertex Pharmaceuticals COM 92532F100 1,519 -62 -3.92 479 4.82 0.0045
2023-01-18 2022-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,581 -20 -1.25 457 -1.72 0.0046
2022-11-08 2022-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,601 -17,578 -91.65 464 -91.41 0.0050
2022-08-02 2022-06-30 13F Vertex Pharmaceuticals COM 92532F100 19,179 17,028 791.63 5,404 863.28 0.0517
2022-04-20 2022-03-31 13F Vertex Pharmaceuticals COM 92532F100 2,151 -1,302 -37.71 561 -25.99 0.0048
2022-01-28 2021-12-31 13F Vertex Pharmaceuticals COM 92532F100 3,453 -666 -16.17 758 1.47 0.0058
2021-11-08 2021-09-30 13F Vertex Pharmaceuticals COM 92532F100 4,119 -337,617 -98.79 747 -98.92 0.0058
2021-08-05 2021-06-30 13F Vertex Pharmaceuticals COM 92532F100 341,736 -615 -0.18 68,904 -6.34 0.5763
2021-05-05 2021-03-31 13F Vertex Pharmaceuticals COM 92532F100 342,351 29,923 9.58 73,568 -0.37 0.6644
2021-01-26 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 312,428 10,938 3.63 73,839 -10.00 0.6955
2020-11-03 2020-09-30 13F Vertex Pharmaceuticals COM 92532F100 301,490 2,844 0.95 82,041 -5.37 0.8883
2020-07-23 2020-06-30 13F Vertex Pharmaceuticals COM 92532F100 298,646 -5,099 -1.68 86,700 19.96 1.0303
2020-04-21 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 303,745 -3,672 -1.19 72,276 7.38 1.1008
2020-02-10 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 307,417 -1,439 -0.47 67,309 28.63 0.8195
2019-11-01 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 308,856 5,779 1.91 52,326 -5.85 0.6737
2019-08-07 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 303,077 22,210 7.91 55,578 7.57 0.7053
2019-05-08 2019-03-31 13F Vertex Pharmaceuticals COM 92532F100 280,867 2,319 0.83 51,665 11.93 0.6758
2019-01-25 2018-12-31 13F Vertex Pharmaceuticals COM 92532F100 278,548 17,172 6.57 46,158 -8.38 0.6941
2018-10-26 2018-09-30 13F Vertex Pharmaceuticals COM 92532F100 261,376 8,644 3.42 50,378 17.28 0.6516
2018-07-25 2018-06-30 13F Vertex Pharmaceuticals COM 92532F100 252,732 199,510 374.86 42,954 908.07 0.5912
2013-08-08 2013-06-30 13F Vertex Pharmaceuticals COM 92532F100 53,222 53,222 4,261 0.1264
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.